Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on March 8, 2024. The filing serves to announce the Company's financial results for the fourth quarter and full year ended December 31, 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not explicitly list material changes versus prior periods within the text body. It directs readers to the press release for the full year and fourth-quarter results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash position figures in the Exhibit 99.1 Press Release dated March 8, 2024.
- Confirm the Company's cash runway and burn rate based on the full-year 2023 results.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the Company's lead candidates.
- Note that the filing text explicitly excludes the financial data from being "filed" under Section 18 of the Exchange Act.